Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers
Journal of Pediatric Endocrinology & Metabolism
This can result in possible sepsis with fatal organ damage (3)
Thyroid: Off J Am Thyroid Assoc (2011) 21(5):5634
NOTE: The LVLUP HEALTH brand product line is exclusive to authorized physician retailers and cannot be resold
When to Seek Medical Advice About Skin Reactions Whilst Ozempic is not known to cause photosensitivity, any new or concerning skin changes warrant medical attention, particularly for people with diabetes who may be at increased risk of skin complications
